No registrations found.
ID
Source
Health condition
precachexia, cachexia, cancer
precachexie, cachexie, kanker
Sponsors and support
Intervention
Outcome measures
Primary outcome
To determine the prevalence of (pre)cachexia (based on the current definition) in patients with advanced cancer scheduled for treatment with chemotherapy.
Secondary outcome
1. To determine the prevalence of pre-cachexia and cachexia related to the type of tumour (part 1, not-WMO);
2. To determine the reproducibility and validity of the measurement of pre-cachexia and cachexia at two consecutive time points (at minimum one week apart from each other) in one patient (part 1, not-WMO);
3. To determine whether potential biomarkers of pre-cachexia can be identified in a subgroup of cancer patients with stage III/IV non-small cell lung cancer (part 2, WMO).
Background summary
Cachexia is a frequently observed syndrome in cancer patients. It reversely impacts quality of life and is linearly and prognostically related to clinical outcome but cannot be fully reversed by conventional nutritional therapy. In contrast to cachexia, pre-cachexia is expected to be a still reversible state that may respond to nutritional intervention. Recently, an expert-opinion of pre-cachexia has been put forward that can be used for the early identification, and subsequently for the early treatment, of pre-cachexia. The current proposal aims to study the prevalence of pre-cachexia and cachexia, to identify patient groups at increased risk and to explore potential biomarkers of pre-cachexia.
Study objective
Cachexia is a frequently observed syndrome in cancer patients. It reversely impacts quality of life and is linearly and prognostically related to clinical outcome but cannot be fully reversed by conventional nutritional therapy. In contrast to cachexia, pre-cachexia is expected to be a still reversible state that may respond to nutritional intervention. Recently, an expert-opinion of pre-cachexia has been put forward that can be used for the early identification, and subsequently for the early treatment, of pre-cachexia. The current proposal aims to study the prevalence of pre-cachexia and cachexia, to identify patient groups at increased risk and to explore potential biomarkers of pre-cachexia.
Study design
Cross-sectional design (try for 2 measurements with one week in between).
Intervention
Two interviews of at maximum 30 minutes (with one week in between), including 3 small self-administered questionnaires, 2 VAS-scales and a measurement of body composition. In addition, 60 patients with stage III/IV non-small cell lung cancer are asked for extra blood collection during (two tubes) routinely collected blood in fasted state to identify potential biomarkers of pre-cachexia and cachexia.
P.O. Box 7057
M.A.E. Bokhorst - de van der Schueren, van
De Boelelaan 1117
Amsterdam 1007 MB
The Netherlands
m.vanbokhorst@vumc.nl
P.O. Box 7057
M.A.E. Bokhorst - de van der Schueren, van
De Boelelaan 1117
Amsterdam 1007 MB
The Netherlands
m.vanbokhorst@vumc.nl
Inclusion criteria
4.2.1 Inclusion criteria for cohort (part 1, not-WMO):
1. Adults (> 18 years);
2. Advanced breast cancer, colorectal cancer, hormone refractory prostate cancer or stage III/IV non small cell lung cancer;
3. Treatment plan: Palliative chemotherapy or in the case of stage III NSCLC: chemoradiation.
Exclusion criteria
1. Ascites (for which treatment is necessary) or serious pitting edema;
2. Chemotherapy treatment in the past month;
3. Not able to speak the Dutch language;
4. Pregnancy.
Design
Recruitment
Followed up by the following (possibly more current) registration
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL2947 |
| NTR-old | NTR3094 |
| CCMO | NL37535.029.11 |
| ISRCTN | ISRCTN wordt niet meer aangevraagd. |
| OMON | NL-OMON35709 |